Vanderbilt’s David Robertson, M.D., and Meena Madhur, M.D., Ph.D., were recognized by the American Heart Association’s Council on Hypertension during the annual Council on Hypertension Scientific Sessions meeting in Orlando this week.

Increased activity of the “fight or flight” nervous system contributes to obesity-associated hypertension and may be a good therapeutic target for the disease.

The number and percentage of patients treated at emergency departments for hypertension are on the rise across the United States, according to a Vanderbilt study published recently in The American Journal of Cardiology.

The initial results of a landmark clinical trial sponsored by the National Institutes of Health (NIH) indicate lowering systolic blood pressure below a commonly recommended target significantly reduces rates of cardiovascular events and lowers risk of death in a group of adults 50 years and older.

Changes in the kidney can limit the blood pressure-lowering effects of thiazide diuretics, a new study reports.

Despite prior epidemiologic and experimental data to the contrary, new research shows that vitamin D supplementation does not reduce blood pressure in individuals with prehypertension or stage I hypertension and vitamin D deficiency.

The evidence is increasing: the immune system and inflammation are key contributors to high blood pressure.